Navigation Links
Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent
Date:5/5/2010

NEW YORK, NY MAY 6, 2010 Results from the SPIRIT IV clinical trial, which were first presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium, were published today in the New England Journal of Medicine.

Data from the trial, a large-scale multi-center study of nearly 4,000 patients in the U.S., showed that everolimus-eluting stents demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to paclitaxel-eluting stents. The trial, which was powered for superiority for clinical endpoints without angiographic follow up, also examined the differences in performance of the two stents in patients with diabetes.

"The data published in today's New England Journal of Medicine, and first reported at TCT, demonstrate enhanced safety and efficacy of the everolimus-eluting stent compared to the paclitaxel-eluting stent in this large-scale study without routine angiographic follow-up. The study results also suggest that minimal late loss may be achieved with drug-eluting stents without sacrificing safety," said principal investigator Gregg W. Stone, MD, Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation.

The primary endpoint of the trial was target-lesion failure (TLF) at one year, a composite measure of cardiac death, target-vessel heart attack or ischemia-driven target-lesion revascularization (TLR). Major secondary endpoints of the trial were ischemia-driven TLR at one year, and the composite rate of cardiac death or target-vessel heart attack at one year.

For everolimus-eluting stents, TLF at one year was 4.2 percent, and for paclitaxel-eluting stents, TLF was 6.8 percent, a significant 38 percent reduction.

At one-year, ischemia-driven TLR was 2.5 percent for everolimus-eluting stents and 4.6 percent for paclitaxel-eluting stents, a significant 45 percent reduction.

The composite rates of cardiac death or target-vessel myocardial infarction through one year were not statistically different with the 2 stents (2.2 percent for everolimus-eluting stents and 3.2 percent for paclitaxel-eluting stents). The one-year rates of myocardial infarction and stent thrombosis, however, were also lower with everolimus-eluting stents than with paclitaxel-eluting stents (1.9 percent vs. 3.1 percent for myocardial infarction and 0.17 percent vs. 0.85 percent stent thrombosis.)

The results were consistent regardless of lesion length, vessel size and the number of lesions treated. However, in the diabetic-patient subgroup, the study found a comparable rate of TLF with both stents, whereas in patients without diabetes, everolimus-eluting stents reduced TLF by 53 percent compared to paclitaxel-eluting stents.

"Outcomes in patients with diabetes may still be improved, and should represent an area of focus for future development of novel drugs and enhanced stent design," Dr. Stone said.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. New Study Shows Parents How to Increase Their Kid's Success in Reading
2. Men With HPV at Higher Risk for HIV, Study Finds
3. Study finds cutting colonoscopy preparation from 2 days to 1 day just as effective
4. Study finds key protein controls T-cell proliferation
5. Pay-for-performance programs may worsen medical disparities, study finds
6. Phase II study of an oral therapy for Gaucher disease yields positive results
7. Most common cancers in the world decreasing in Alberta: Study
8. For Younger Women, Mammograms Not Too Effective: Study
9. Prostate Cancer Test a Flop in Study
10. Study Published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association Shows Algal DHA Improved Memory and Learning in Healthy Adults Age 55 and Older
11. Study evaluates importance of timeliness of care in breast cancer diagnosis and treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian ... January ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings ... quality of its beauty and wellness products. At this trade show, the company had ...
(Date:1/21/2017)... , ... January 21, 2017 , ... "ProDOF is the perfect set of tools for ... another subject in a scene," said Christina Austin - CEO of Pixel Film Studios. ... Easily create the illusion of a DSLR racking focus from one area into the ...
(Date:1/21/2017)... ... 2017 , ... Phytocéane invites you to take an exotic journey ... world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a Tanzanian archipelago ... moisturizing vegetal coral to create this gentle, crystal-clear shower gel to cleanse the body ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... that Redwood Family Dermatology has recently joined their multi-specialty medical group. ... full range of cosmetic services. , “We’re excited to add this excellent dermatology ...
(Date:1/21/2017)... ... 2017 , ... In the United States, 20 million women and 10 million ... often feel shame for having struggled with an eating disorder as well as common ... Strong in Life After an Eating Disorder” -- to be featured at this year’s ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 /PRNewswire/ ... reach USD 233.7 billion by 2025, according to ... The market is anticipated to be predominantly driven ... companies, resulting into the large-scale production of new ... widen the influx of drugs at an unprecedented ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology: